Context Therapeutics Ownership
| CNTX Stock | USD 0.84 0 0.12% |
Context |
Context Stock Ownership Analysis
About 97.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.74. Some equities with similar Price to Book (P/B) outperform the market in the long run. Context Therapeutics recorded a loss per share of 0.89. The entity had not issued any dividends in recent years. Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania. Context Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. For more info on Context Therapeutics please contact the company at 267 225 7416 or go to https://www.contexttherapeutics.com.Besides selling stocks to institutional investors, Context Therapeutics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Context Therapeutics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Context Therapeutics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Context Therapeutics Quarterly Liabilities And Stockholders Equity |
|
Roughly 3.0% of Context Therapeutics are currently held by insiders. Unlike Context Therapeutics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Context Therapeutics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Context Therapeutics' insider trades
Context Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Context Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Context Therapeutics backward and forwards among themselves. Context Therapeutics' institutional investor refers to the entity that pools money to purchase Context Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Ally Bridge Group (ny) Llc | 2024-12-31 | 1.6 M | Woodline Partners Lp | 2024-12-31 | 1.4 M | Sio Capital Management, Llc | 2024-12-31 | 1.3 M | Affinity Asset Advisors, Llc | 2024-12-31 | 1 M | Allostery Investments Lp | 2024-12-31 | 950.2 K | Blackrock Inc | 2024-12-31 | 912.4 K | Ubs Group Ag | 2024-12-31 | 699.1 K | Geode Capital Management, Llc | 2024-12-31 | 628.7 K | Adar1 Capital Management Llc | 2024-12-31 | 351.1 K | Mpm Oncology Impact Management Lp | 2024-12-31 | 14.7 M | Avidity Partners Management Lp | 2024-12-31 | 7.5 M |
Context Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Context Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Context Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Context Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Context Therapeutics Outstanding Bonds
Context Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Context Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Context bonds can be classified according to their maturity, which is the date when Context Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Context Stock Analysis
When running Context Therapeutics' price analysis, check to measure Context Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Context Therapeutics is operating at the current time. Most of Context Therapeutics' value examination focuses on studying past and present price action to predict the probability of Context Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Context Therapeutics' price. Additionally, you may evaluate how the addition of Context Therapeutics to your portfolios can decrease your overall portfolio volatility.